Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues

被引:17
作者
Simsir, A [1 ]
Palacios, D [1 ]
Linehan, WM [1 ]
Merino, MJ [1 ]
Abati, A [1 ]
机构
[1] NIH, NCI, Pathol Lab, Cytopathol Sect, Bethesda, MD 20892 USA
关键词
chromosome; 3; loss of heterozygosity; clear-cell carcinoma; ovary;
D O I
10.1002/dc.1070
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Loss of heterozygosity (LOH) at the 3p region is Sound in lip to 50% of epithelial ovarian neoplasms. The von Hippel-Lindau (VHL) gene at the 3p25 locus is one of the the tumor-suppressor genes located at 3p. The role, if any, of the VHL gene locus is not clear in ovarian carcinogenesis. We analyzed primary and metastatic ovarian clear-cell carcinomas (OCCC) for LOH at 3p25 to determine its frequency and its diagnostic utility as an adjunctive tool in rite differential diagnosis of metastatic clear-cell carcinomas. Microdissection followed by single-step DNA extraction and polymerase chain reaction (PCR) amplification, using two polymorphic markers flanking the VHL gene locus, was done on archival histology and cytology samples from 9 patients with metastatic OCCC. Of the informative cases, 43% of the metastatic and 50% of the primary OCCC showed LOH. LOH at the VHL gene locus is not uncommon in clear-cell ovarian carcinoma. LOH at 3p25 in cytologic specimens may be a valuable adjunct in the diagnosis of OCCC metastasis in cytologically equivocal cases. OCCC should enter rite differential in clear-cell carcinomas of unknown primary that show LOH at 3p25. Published 2001 Wiley-Liss, Inc.
引用
收藏
页码:328 / 332
页数:5
相关论文
共 23 条
  • [1] Abati A, 1999, CANCER CYTOPATHOL, V87, P231, DOI 10.1002/(SICI)1097-0142(19990825)87:4<231::AID-CNCR11>3.3.CO
  • [2] 2-1
  • [3] Beaty MW, 1997, CANCER CYTOPATHOL, V81, P180, DOI 10.1002/(SICI)1097-0142(19970625)81:3<180::AID-CNCR8>3.3.CO
  • [4] 2-1
  • [5] CHEN F, 1995, CANCER RES, V55, P4804
  • [6] Chuaqui R, 1996, ACTA CYTOL, V40, P642
  • [7] DODSON MK, 1993, CANCER RES, P4456
  • [8] EHLEN T, 1990, ONCOGENE, V5, P219
  • [9] Utilization of molecular genetics in the differentiation between adrenal cortical adenomas and carcinomas
    Fogt, F
    Vargas, MP
    Zhuang, ZP
    Merino, MJ
    [J]. HUMAN PATHOLOGY, 1998, 29 (05) : 518 - 521
  • [10] Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours
    Foster, K
    Osborne, RJ
    Huddart, RA
    Affara, NA
    FergusonSmith, MA
    Maher, ER
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2392 - 2395